Loading...
•
Dec 31, 2024
AbCellera Q4 2024 Earnings Report
AbCellera reported fourth quarter results, highlighting revenue and net loss figures.
Key Takeaways
AbCellera reported Q4 2024 revenue of $5.1 million and a net loss of $34.2 million. The company continues to advance its pipeline and invest in its capabilities.
Revenue for Q4 2024 was $5.1 million, primarily from research fees.
Operating expenses for Q4 2024 totaled $77.8 million, including investments in co-development and internal programs.
Net loss for Q4 2024 was $34.2 million, or $(0.12) per share.
Abdera advanced ABD-147 into a Phase 1 clinical trial.
AbCellera
AbCellera
AbCellera Revenue by Segment
Revenue by Segment
Research Fees Revenue
CapyFin.com Forward Guidance
AbCellera is on track to initiate Phase 1 clinical trials for ABCL635 and ABCL575 and start activities in its new clinical manufacturing facility in 2025.